Clinical Trials Logo

Clinical Trial Summary

COVID-19 Infection was characterized as a Pandemic by WHO on the 11th of March 2020.1 After this there were all possible worldwide efforts to increase awareness in the general population about the COVID-19 Infection signs, symptoms, mode of transmission and prevention. The information was spread across all possible mass media communication channels. There were constant updates regarding the data of newly infected cases, deaths, and recoveries. This cross sectional study is conducted with the following objectives:

1. To understand the netizens perception regarding the sources of information available on COVID-19.

2. To understand the netizens populations perception regarding the available information on COVID-19.


Clinical Trial Description

Mass media plays a significant role in public outreach and create awareness. Various mass media has their individual reach to the general public. In the current world of information technology availability of information is not an issue. There is in fact excessive availability of information. What makes a big difference is that RIGHT information delivery on RIGHT time and within RIGHT time. After WHO characterized COVID-19 infection as pandemic, mass media played a significant role in creating awareness regarding COVID-19 infection signs, symptoms, mode of transmission and its prevention. There were constant updates in various mass media regarding the data of newly infected cases, deaths, and recoveries. COVID-19 Pandemic has created fears, anxiety, and worries among the general population. There was information given to general public regarding treatment drugs and possibility of vaccine for COVID-19 infection. This created a ray of hope in many. So information in various mass media sources had different types of impact on general population thoughts.

This cross sectional study is conducted with the following objectives:

1. To understand the general populations perception regarding the sources of information available on COVID-19.

2. To understand the general populations perception regarding the available information on COVID-19.

This Cross sectional study utilizes an electronic google form to get responses from netizens of Al Qassim province of Saudi Arabia regarding the perception of COVID-19 information and information sources. All the questions in the survey are compulsory answerable questions. The settings in the google form are set so that a single respondent can limit the survey response to single time. The Survey Questionnaire contained following sections:

Section I: Minimum required personal details Section II: 10 Questions regarding the source of COVID-19 information Section III: 6 Questions regarding perception of the COVID-19 information

The questionnaire also carried the following disclaimer:

"This Survey will not Collect your Name, Email, Location, and Phone number. We pledge that the data obtained by this survey is for Educational purpose & scientific knowledge enhancement only. The data will not be transferred or shared with any other third party for commercial interest."

The very first part of the Questionnaires seeks responders' consent for giving responses to the survey questions. participation Section II & III contained all closed ended questions. The Google form link is shared to the netizens of Al Qassim province across relevant Social media platforms. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04497441
Study type Observational
Source Qassim University
Contact Bugude Shiva Shankar, MDS
Phone +966163020523
Email S.ggg@qu.edu.sa
Status Recruiting
Phase
Start date June 10, 2020
Completion date August 15, 2020

See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3